The Oropouche virus, transmitted by mosquitoes and biting midges, may be far more widespread in Latin America than previously understood, according to a study published in April 2025 in The Lancet Infectious Diseases. Closely related to Zika and Dengue, Oropouche poses significant risks to pregnant women, being linked to stillbirths and severe birth defects. While endemic in Brazil, particularly in the Amazon rainforest, the virus began rapidly spreading across South America and the Caribbean starting in October 2023, with over 20,000 confirmed cases and four deaths reported. However, new research led by scientists from the Charité Institute of Virology in Germany analyzed 9,400 blood samples collected between 2001 and 2022 from Bolivia, Colombia, Costa Rica, Ecuador, and Peru, finding that 6.3%—approximately 600 individuals—had antibodies against Oropouche, indicating prior infections. This suggests the virus has been circulating in the region for over two decades, massively underdiagnosed due to its symptoms’ similarity to dengue, including high fever, muscle pain, and headaches. The 2023-2024 El Niño phenomenon, intensified by climate change, also boosted the proliferation of vector insects, increasing transmission.
The virus’s prevalence varies across regions. In Costa Rica, only 2% of samples showed antibodies, while Ecuador reported 5%, and the Amazon region exceeded 10%. Low-altitude, warm, humid areas exhibited higher incidence, favoring the reproduction of transmitting insects. The study underscores the urgent need to develop an Oropouche vaccine, which does not yet exist, and to train healthcare professionals to recognize its symptoms, particularly in cases of unexplained fevers, pregnancy complications, or unexplained deaths.
The impact of Oropouche extends beyond public health, affecting rural and urban communities in countries where healthcare systems already struggle with tropical diseases. The research warns that the virus could become even more prevalent as climate change progresses, creating ideal conditions for mosquito proliferation. Latin America, already battling recurrent outbreaks of dengue and Zika, now faces the threat of an emerging disease, requiring coordinated efforts for monitoring, diagnosis, and prevention.
- Underdiagnosis: 6.3% of blood samples reveal past Oropouche infections.
- Risk to pregnant women: Virus linked to stillbirths and congenital defects.
- El Niño impact: 2023-2024 phenomenon intensified transmission.
- Urgent vaccine need: Study highlights necessity for Oropouche immunization.
Reach of Oropouche in Latin America
The research, spanning 2001 to 2022, revealed that Oropouche has been present in multiple Latin American countries far longer than official records suggested. Of the 9,400 blood samples analyzed, 592 tested positive for Oropouche antibodies, indicating that thousands may have been infected without diagnosis. Prevalence was highest in tropical regions like the Amazon, where over 10% of samples were positive, while higher-altitude areas, such as parts of Bolivia and Peru, showed lower rates due to fewer mosquitoes and midges in colder environments.
In Colombia, the detection of antibodies in both urban and rural areas suggests the virus is not confined to forested regions but can circulate in densely populated cities. Ecuador’s 5% positive sample rate reflects the vulnerability of coastal areas, where climate conditions favor vectors. Costa Rica, with only 2% prevalence, appears less affected, possibly due to robust mosquito control systems. These findings indicate that Oropouche is not just a seasonal threat but a persistent concern in tropical Latin America.
The virus’s underreporting is exacerbated by its symptom overlap with dengue, a widespread regional endemic. High fever, joint pain, and headaches often lead doctors to assume dengue without testing for Oropouche. This diagnostic confusion contributes to the lack of accurate data on the virus’s true extent, hindering control and prevention efforts.
Public health impacts
Oropouche poses a significant challenge to Latin America’s healthcare systems, particularly in resource-constrained countries. Its association with pregnancy complications, such as stillbirths and birth defects, raises concerns similar to those seen during the 2015-2016 Zika epidemic. While the exact mechanisms of Oropouche’s impact on fetuses are still under investigation, the presence of antibodies in populations across five countries suggests the virus may have caused silent harm for years, undetected.
Hospitals and clinics in regions like Bolivia and Peru, where access to diagnostic tests is limited, struggle to differentiate Oropouche from other arboviruses. The absence of a vaccine or specific treatment worsens the situation, leaving insect bite prevention as the primary control measure. Public health campaigns, already focused on eliminating mosquito breeding sites for dengue, need expansion to address midges, less familiar but equally dangerous vectors.
The rapid spread of Oropouche since 2023, with over 20,000 confirmed cases in under two years, highlights its potential to proliferate in urban areas. Cities like Manaus, Brazil, and Guayaquil, Ecuador, reported significant outbreaks, straining healthcare systems already burdened by other tropical diseases. Robust epidemiological surveillance is clearly needed, especially in regions where the virus may be circulating undetected.
Role of El Niño and climate change
The 2023-2024 El Niño phenomenon, one of the strongest on record, played a critical role in Oropouche’s spread. Characterized by warmer temperatures and heavy rainfall, El Niño created ideal conditions for mosquito and midge proliferation, boosting virus transmission in countries like Bolivia, Colombia, and Peru. Abundant rains led to water pooling, perfect for insect breeding, while elevated temperatures accelerated their life cycles.
Climate change, which intensified El Niño, further contributes to Oropouche’s expansion. Global warming is altering Latin America’s weather patterns, extending rainy seasons and raising temperatures in areas previously less prone to arboviruses. Low-altitude regions, such as the Amazon and Ecuador’s coast, are particularly affected, but even moderately elevated urban areas are starting to report cases. The forecast of more frequent extreme weather events in coming years suggests Oropouche could become a greater threat.
The interplay between climate and public health demands integrated responses. Beyond vector control campaigns, governments need to invest in infrastructure to mitigate rainfall impacts, such as urban drainage systems, and in research to better understand Oropouche vector ecology. Inaction could lead to more severe outbreaks, particularly in vulnerable communities.
- El Niño 2023-2024: Heavy rains increased mosquito breeding sites.
- Climate change: Global warming expands Oropouche’s reach.
- High-risk areas: Amazon and coastal regions show higher prevalence.
- Climate prevention: Urban drainage and vector control are critical.
Challenges in diagnosis and surveillance
Diagnosing Oropouche is a major challenge due to its similarity to dengue and other arboviruses. Serological tests, like those used in the 2025 study, effectively detect past infections but are not widely available in public health clinics. PCR tests, which identify active virus, are even rarer, especially in rural Bolivia and Peru. As a result, many cases are recorded as dengue or simply unexplained fevers, masking the problem’s true scope.
Epidemiological surveillance in Latin America faces obstacles. Notification systems in countries like Colombia and Ecuador are fragmented, with inconsistent data between urban and rural areas. The lack of integration between health ministries and environmental authorities hinders effective preventive strategies. For instance, Oropouche outbreaks in Amazonian areas often go undetected for weeks, spreading to nearby cities.
Training healthcare professionals is a priority highlighted by the study. Doctors and nurses need education to suspect Oropouche in cases of persistent fever, especially in pregnant women, and to request specific tests when available. Establishing regional laboratory networks for arbovirus analysis could also improve detection, enabling faster outbreak responses.
Urgent need for a vaccine
The absence of an Oropouche vaccine is one of the biggest barriers to disease control. Unlike dengue, which has vaccines in use in some countries, Oropouche research is in early stages. The 2025 study emphasizes that developing a vaccine is critical, given the virus’s impact on pregnant women and its rapid spread. Efforts face challenges, including limited funding and the complexity of creating vaccines for lesser-known arboviruses.
Without a vaccine, prevention relies on measures like repellents, window screens, and breeding site elimination. However, these are less effective against midges, which are smaller and harder to control than mosquitoes. Rural communities, with limited access to repellents and screens, are particularly vulnerable, requiring targeted public health campaigns.
International organizations, such as the Pan American Health Organization (PAHO), are beginning to prioritize Oropouche, but progress is slow. Collaboration between governments, universities, and pharmaceutical companies will be crucial to accelerate vaccine and treatment development, reducing the virus’s regional impact.
Impact on Amazonian communities
Amazonian communities, where Oropouche is endemic, face the greatest challenges. In Brazil, cities like Manaus and Belém reported significant outbreaks since 2023, overwhelming hospitals and lacking diagnostic tests. The study’s finding of over 10% antibody prevalence in the Amazon indicates intense regional circulation, affecting both indigenous and urban populations.
Limited healthcare infrastructure in remote areas exacerbates the issue. Many communities rely on boats or planes to reach hospitals, and delays in care can be fatal in severe cases. Pregnant women, at risk of complications, often lack adequate follow-up, increasing stillbirths and birth defects.
Beyond health, Oropouche impacts local economies. Communities reliant on agriculture and tourism face difficulties when outbreaks deter visitors or disrupt farming. Support programs, such as distributing prevention kits and building health posts, are vital to protect these populations.
- Amazon at risk: Over 10% of samples show antibodies in the region.
- Poor healthcare: Remote communities lack access to tests or treatments.
- Economic impact: Outbreaks affect agriculture and tourism.
- Needed support: Prevention kits and health posts for isolated areas.
Prospects for Oropouche control
Controlling Oropouche requires a multifaceted approach, combining surveillance, research, and community action. Early warning systems integrating climate and epidemiological data can predict outbreaks and allocate resources to high-risk areas. For example, monitoring rainfall and temperatures can signal periods of heightened vector activity, enabling timely interventions.
Public education is also critical. Campaigns teaching communities to identify midge breeding sites, such as water pools and dense vegetation, can reduce transmission. Schools and community leaders should be involved to spread information, especially in rural areas with limited media access. Successful dengue control initiatives, like cleanup drives, can serve as models.
Regionally, cooperation among Latin American countries is essential. Oropouche crosses borders, and outbreaks in Brazil can quickly spread to Bolivia and Peru. A regional consortium for arbovirus research and response could accelerate vaccine development and improve information sharing.
Oropouche timeline in Latin America
The Oropouche virus has a history of silent spread, with key milestones in recent years.
- 2001-2022: Antibodies detected in 6.3% of blood samples across five countries.
- October 2023: First confirmed cases outside Brazil in South America and the Caribbean.
- 2023-2024: El Niño fuels outbreaks, with over 20,000 cases and four deaths.
- April 2025: Study reveals underdiagnosis and circulation since 2001.
Tips for Oropouche prevention
Protecting against Oropouche requires practical measures, especially in tropical areas. Some tips can help.
- Use repellent: Apply DEET-based products to exposed skin.
- Install screens: Use window and door screens to block midges.
- Eliminate breeding sites: Remove standing water and clear dense vegetation.
- Wear long clothing: Cover arms and legs in high-risk areas.
- Seek medical help: Consult doctors for persistent fever, especially in pregnancy.
Future impact and regional challenges
Oropouche has the potential to become a greater threat in Latin America, especially with advancing climate change. Intensified rains and rising temperatures create favorable conditions for vectors, expanding the virus’s reach to new areas. Urban centers like Bogotá and Lima may start reporting cases, straining healthcare systems already pressured by dengue and other diseases.
Economic challenges are also significant. Oropouche outbreaks can deter tourists from popular destinations like the Amazon and Ecuador’s coast, impacting local revenue. Agriculture, a vital sector, faces losses when outbreaks disrupt farming, threatening food security in rural areas.
Addressing the crisis requires a long-term vision. Investments in research, healthcare infrastructure, and public education are essential to mitigate Oropouche’s impact. Collaboration among governments, international organizations, and local communities will be crucial to tackle this emerging threat, safeguarding the health and well-being of millions in Latin America.